PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Duloxetine - Pain (Neuropathic)
PAD Profile : Duloxetine - Pain (Neuropathic) Important
Keywords :
neuropathic pain, diabetic neuropathy, postherpetic neuralgia, PHN
Brand Names Include :
Cymbalta
Important Information :
Licensed only for diabetic peripheral neuropathic pain but also recommended as per NICE CG173 (off- label indication) as a treatment option in neuropathic pain.
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
- Amitriptyline hydrochloride
- Gabapentin
- Pregabalin
- Nortriptyline
- Imipramine hydrochloride
- Dosulepin hydrochloride
- Tramadol hydrochloride
- Capsaicin
Other Indications
Additional Documents
Type
Document
Review Date
Committee Recommendations
Date
Committee Name
Narrative
07 October 2020
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
Duloxetine 60mg once daily or amitriptyline are recommended as treatment options at step 1 of the local neuropathic pain guidelines..
Duloxetine is licensed only for diabetic peripheral neuropathic pain but is also recommended by NICE as a treatment option in neuropathic pain.
See guidelines below.
03 May 2017
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
GENERIC Duloxetine has been considered by the PCN and has been assigned a GREEN traffic light status
NOTE - the branded product, Cymbalta, was considered BLACK at the PCN in May 2017.
Associated BNF Codes
04. Central Nervous System
04.07.03. Neuropathic pain